Loading organizations...
§ Private Profile · 70 Willow Road, Menlo Park, CA 94025
Biopharmaceutical company developing immuno-oncology and genetic medicine therapeutics, funded by venture capital.
Key people at Hawkeye Therapeutics.
Hawkeye Therapeutics is a biopharmaceutical company dedicated to developing innovative therapeutics, with its specific headquarters location not publicly disclosed. The organization focuses on addressing unmet medical needs, potentially in areas such as immuno-oncology, immuno-neurology, or genetic medicines, though detailed information on its product pipeline remains limited. Its business model is centered on venture capital funding, with Frazier Healthcare Partners identified as a key investor. Frazier Healthcare Partners is known for its extensive activity in the biotech sector, including its involvement with companies like Arcutis Biotherapeutics (NASDAQ: ARQT). While specific financial metrics, employee counts, or founding details for Hawkeye Therapeutics are not publicly available, the company has been noted in discussions concerning emerging biotech entities, such as Recode Therapeutics, indicating its presence within the broader biopharmaceutical landscape.
Key people at Hawkeye Therapeutics.
Hawkeye Therapeutics refers to multiple entities across search results, but the most prominent innovative profile is Hawkeye Bio (also referenced as Hawkeye Therapeutics in collaborations), a biotech startup developing early cancer detection technology. It builds LEAP technology, a blood-based test measuring cancer-related enzyme activity in asymptomatic individuals to enable early detection of cancers like lung cancer, when most treatable. The product targets patients and healthcare providers seeking non-invasive, affordable screening, solving the problem of late-stage cancer diagnosis by offering a 100% safe, fast, and low-cost alternative to traditional methods. A separate Hawkeye Therapeutics, Inc. collaborated on pharmaceutical formulations with Arcutis Biotherapeutics, indicating formulation development expertise.[3][4][5]
An older, unrelated entity, Hawkeye Therapeutics L.L.C., is a durable medical equipment supplier (NPI since 2009) providing items like wheelchairs and respirators, with no recent activity noted.[2] This analysis focuses on the biotech entity due to its alignment with tech/biotech investment contexts.
Hawkeye Bio's origins center on its co-founder and CEO, who leads a small team (<25 employees) in Westlake Village, California, including roles like Product Development Scientist and Assay Development Scientist. The idea emerged from developing a differentiated approach to measure cancer enzyme activity for early detection in undiagnosed individuals, addressing a critical gap in oncology.[3][5]
Hawkeye Therapeutics, Inc. gained visibility through a formulation collaboration agreement with Arcutis Biotherapeutics (now Arcutis, Inc.), an early-stage pharma company, focusing on R&D for new pharmaceutical formulations—likely a pivotal moment in its trajectory.[4][6] No specific founding year or detailed founder backgrounds are available, but the company's limited operating history suggests early-stage status.[6]
Hawkeye rides the early cancer detection trend, fueled by advances in liquid biopsies and AI-driven diagnostics, where timing is critical as global cancer cases rise and survival rates plummet post-metastasis. Market forces like demand for non-invasive screening (projected multi-billion market) and post-pandemic health monitoring favor scalable blood tests.[3][5] It influences the ecosystem by democratizing access—potentially reducing healthcare costs and improving outcomes—while competing with players like Grail or Guardant Health, but differentiated by enzyme-focused, cost-effective tech.
Hawkeye Bio is poised for growth with its lung cancer test launch, potentially capturing share in precision oncology amid rising VC interest in diagnostics. Trends like multimodal biomarkers and regulatory fast-tracks (e.g., FDA breakthrough designations) will shape its path, with partnerships like Arcutis signaling scalability.[4][5] Influence may evolve through acquisitions or expansions into multi-cancer panels, amplifying impact in beating cancer through accessible early detection—tying back to its core mission of saving lives affordably. Limited public data suggests monitoring clinical validations and funding rounds for momentum.
